Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2024-03-05
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 6
- Registration Number
- NCT04816214
- Locations
- 🇸🇬
Novartis Investigative Site, Singapore, Singapore
Intratumoral Cisplatin for Resectable NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2022-05-23
- Lead Sponsor
- University of Vermont
- Target Recruit Count
- 10
- Registration Number
- NCT04809103
- Locations
- 🇺🇸
University of Vermont, Burlington, Vermont, United States
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
- Conditions
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2022-06-01
- Target Recruit Count
- 342
- Registration Number
- NCT04807673
- Locations
- 🇨🇳
Department of minimally invasive esophageal surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-19
- Last Posted Date
- 2022-05-05
- Lead Sponsor
- Shanghai Henlius Biotech
- Registration Number
- NCT04806945
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China
Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-03-18
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Peking University
- Target Recruit Count
- 53
- Registration Number
- NCT04804696
- Locations
- 🇨🇳
Beijing Cancer Hospital / Peking University Cancer Hospital, Beijing, Beijing, China
A Study of HB002.1T Plus Chemotherapy in Subjects With Solid Tumor
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Huabo Biopharm Co., Ltd.
- Target Recruit Count
- 72
- Registration Number
- NCT04802980
- Locations
- 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China
Pamiparib and Low Dose Temozolomide In Patients With Platinum Sensitive Biliary Tract Cancer
- Conditions
- Interventions
Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2021-03-08
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Checkpoint Therapeutics, Inc.
- Target Recruit Count
- 25
- Registration Number
- NCT04786964
- Locations
- 🇹🇭
Research Site, Chiang Mai, Thailand
Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 152
- Registration Number
- NCT04774380
- Locations
- 🇹🇷
Research Site, Pamukkale, Turkey
Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC
- First Posted Date
- 2021-02-24
- Last Posted Date
- 2021-02-24
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 200
- Registration Number
- NCT04768075
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.